Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference

By Global News Feed

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on Thursday, February, 16, 2023.

Read more here:
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference

Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

By Global News Feed

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2022, after market close, on Thursday, March 2, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

View original post here:
Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23

By Global News Feed

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

Excerpt from:
Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23

Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023

By Global News Feed

EDISON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its CEO, Robert Foster, PharmD, PhD, will lead it in ringing the Nasdaq Closing Bell on Friday, February 10, 2023.

Read this article:
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023

InMed Submits Form 12b-25

By Global News Feed

VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “Form 10-Q”).

See the rest here:
InMed Submits Form 12b-25

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

By Global News Feed

RADNOR, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at an initial public offering price of $16.00 per share. All of the shares are being offered by Mineralys. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $192.0 million. Shares of Mineralys common stock are expected to begin trading on the Nasdaq Global Select Market on February 10, 2023 under the ticker symbol “MLYS.” The offering is expected to close on February 14, 2023, subject to the satisfaction of customary closing conditions. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Follow this link:
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023

By Global News Feed

ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2022 after the market closes on Tuesday, February 28, 2023.

Go here to see the original:
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023

→←